Antibody conjugate therapeutics: challenges and potential
- PMID: 22003066
- DOI: 10.1158/1078-0432.CCR-11-1417
Antibody conjugate therapeutics: challenges and potential
Abstract
Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody conjugates is marked by hurdles that have been identified and overcome. Early conjugates used mouse antibodies; cytotoxic agents that were immunogenic (proteins), too toxic, or not sufficiently potent; and linkers that were not sufficiently stable in circulation. Investigators have explored 4 main avenues using antibodies to target cytotoxic agents to malignant cells: antibody-protein toxin (or antibody fragment-protein toxin fusion) conjugates, antibody-chelated radionuclide conjugates, antibody-small-molecule drug conjugates, and antibody-enzyme conjugates administered along with small-molecule prodrugs that require metabolism by the conjugated enzyme to release the activated species. Only antibody-radionuclide conjugates and antibody-drug conjugates have reached the regulatory approval stage, and nearly 20 antibody conjugates are currently in clinical trials. The time may have come for this technology to become a major contributor to improving treatment for cancer patients.
©2011 AACR.
Similar articles
-
What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?Am Soc Clin Oncol Educ Book. 2015:e117-25. doi: 10.14694/EdBook_AM.2015.35.e117. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993162
-
Antibody-drug conjugate targets.Curr Cancer Drug Targets. 2009 Dec;9(8):982-1004. doi: 10.2174/156800909790192365. Curr Cancer Drug Targets. 2009. PMID: 20025606 Review.
-
Antibody drug conjugates.Curr Opin Oncol. 2014 Sep;26(5):476-83. doi: 10.1097/CCO.0000000000000108. Curr Opin Oncol. 2014. PMID: 25024051 Review.
-
Targeted cancer therapy: conferring specificity to cytotoxic drugs.Acc Chem Res. 2008 Jan;41(1):98-107. doi: 10.1021/ar700108g. Epub 2007 Aug 18. Acc Chem Res. 2008. PMID: 17705444 Review.
-
Antibody-cytotoxic agent conjugates for cancer therapy.Expert Opin Drug Deliv. 2005 Sep;2(5):873-90. doi: 10.1517/17425247.2.5.873. Expert Opin Drug Deliv. 2005. PMID: 16296784 Review.
Cited by
-
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.EJNMMI Res. 2013 Apr 4;3(1):23. doi: 10.1186/2191-219X-3-23. EJNMMI Res. 2013. PMID: 23557183 Free PMC article.
-
Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy.Exp Hematol Oncol. 2022 Nov 8;11(1):93. doi: 10.1186/s40164-022-00347-1. Exp Hematol Oncol. 2022. PMID: 36348391 Free PMC article. Review.
-
Antibody-Drug Conjugates for Cancer Therapy.Molecules. 2020 Oct 16;25(20):4764. doi: 10.3390/molecules25204764. Molecules. 2020. PMID: 33081383 Free PMC article. Review.
-
High efficiency diffusion molecular retention tumor targeting.PLoS One. 2013;8(3):e58290. doi: 10.1371/journal.pone.0058290. Epub 2013 Mar 11. PLoS One. 2013. PMID: 23505478 Free PMC article.
-
Penetration of Nanobody-Dextran Polymer Conjugates through Tumor Spheroids.Pharmaceutics. 2023 Sep 22;15(10):2374. doi: 10.3390/pharmaceutics15102374. Pharmaceutics. 2023. PMID: 37896133 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
